Neurotensin receptors: A new marker for human ductal pancreatic adenocarcinoma

Gut

Volumn 42, Issue 4, 1998, Pages 546-550

  Reubi, J C ^a   Waser, B ^a   Friess, H ^b   Buchler M ^b   Laissue, J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Dept of Visc and Transplant Surg ^*

Author keywords

Chronic pancreatitis; Ductal pancreatic carcinornas; Endocrine pancreatic tumours; In vivo scintigraphy; Neurotensin receptors; Regulatory peptides

Indexed keywords

ANTINEOPLASTIC AGENT; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR ANTAGONIST; TUMOR MARKER;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CHRONIC PANCREATITIS; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031949569     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.42.4.546     Document Type: Article

References (21)

1. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997;349:485-9.
2. Warshaw AL, Fernandes-Del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-64.
3. Krenning EP, Bakker WH, Breeman WAP, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;I:242-4.
4. Krenning EP, Kwekkeboom DJ, Pauwels S, et al. Somatostatin receptor scintigraphy. Nuclear Medicine Annual 1995; 1995:1-50.
5. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996;125:26-34.
6. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 mRNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455-9.
7. John M, Meyerhof W, Richter D, et al. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 1996;38:33-9.
8. Reubi JC, Horisberger U, Essed CE, et al. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 1988;95:760-3.
9. Buscail L, Saint-Laurent N, Chastre E, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996;56:1823-7.
10. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995;36:1825-35.
11. Shulkes A. Neurotensin. New York: Raven Press, 1994.
12. Ishizuka J, Townsend CM, Thompson JC. Neurotensin regulates growth of human pancreatic cancer. Ann Surg 1993;217:430-46.
13. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969-77.
14. 3-neurotensin. Neuroscience 1987;22:525-36.
15. Korc M, Friess H, Kobrin MS, et al. Growth factors in human pancreatic cancer: update on the role of the epidermal growth factor receptor. Digestive Surgery 1994;11:147-9.
16. Löwenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433-7.
17. 111-In)-and (I)-neurotensin analogues. Tumor Targeting (in press).
18. Beaudet A, Mazella J, Nouel D, et al. Internalization and intracellular mobilization of neurotensin in neuronal cells. Bioehem Pharmacol 1994;47:43-52.
19. 111-In-DTPA-D-Phe-1)-octreotide. Preliminary data of a phase 1 study. Reston, VA: Society of Nuclear Medicine, 1996.
20. 3-octreotide in tumor bearing rodents. J Nucl Med 1997;38(suppl 5):18P.
21. Gully D, Canton M, Goigegrain R, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 1993;90:65-9.